Benlysta is an injectable prescription medication used to treat adults with active systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines. Benlysta is administered by intravenous infusion at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Benlysta may reduce the activity of your immune system and may cause serious side effects, which you should discuss with your doctor. Common side effects include nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis. Benlysta has not been evaluated in patients with severe active lupus nephritis or severe active nervous system lupus, and it has not been studied in combination with other biologics or intravenous cyclophosphamide.
Click here to view Manufacturers Website